SCHEMBL4582050

SCHEMBL4582050

CCOc1ccc(Nc2cccc3ccccc23)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.69
KMT2A Q03164 5/20 0.67
ALDH1A1 P00352 4/20 0.59
HPGD P15428 4/20 0.59
CDC25B P30305 3/20 0.59
TP53 P04637 2/20 0.59
CYP3A4 P08684 1/20 0.59
ALOX15 P16050 1/20 0.59
TSHR P16473 1/20 0.59
ATM Q13315 1/20 0.59
HSD17B10 Q99714 1/20 0.59
KDM4E B2RXH2 5/20 0.58
MAPT P10636 3/20 0.58
POLB P06746 1/20 0.58
OPRM1 P35372 1/20 0.58
OPRD1 P41143 1/20 0.58
RAD52 P43351 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
SLC2A1 P11166 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28438329 0.88 RAB9A (0.66) RAB9AKMT2AALDH1A1HPGDCDC25B
SCHEMBL30273063 0.82 RAB9A (1.00) RAB9AKMT2AALDH1A1HPGDCDC25B
SCHEMBL30273064 0.82 RAB9A (1.00) RAB9AKMT2AALDH1A1HPGDCDC25B
SCHEMBL2114596 0.82 RAB9A (1.00) RAB9AKMT2AALDH1A1HPGDCDC25B
SCHEMBL4796372 0.82 RAB9A (0.75) RAB9AKMT2AALDH1A1HPGDCDC25B
SCHEMBL651572 0.81 HSD17B10 (0.87) RAB9AKMT2AALDH1A1HPGDCDC25B
SCHEMBL29619354 0.81 HSD17B10 (0.87) RAB9AKMT2AALDH1A1HPGDCDC25B
SCHEMBL10346931 0.79 KMT2A (0.61) RAB9AKMT2AALDH1A1HPGDKDM4E
SCHEMBL12258222 0.79 CDC25B (0.65) RAB9AKMT2AALDH1A1HPGDCDC25B
SCHEMBL14407636 0.79 RAB9A (0.71) RAB9AKMT2AALDH1A1HPGDCDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951842-B1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS BASF SE (DE) 2016-07-27 EP disclosed
US-8501046-B2 Use of rylene derivatives as photosensitizers in solar cells BASF SE (DE) 2013-08-06 US disclosed
US-20120283432-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS MAX-PLANCK-GESEL. ZUR FOERDERUNG DER WISSEN. E.V. (DE) 2012-11-08 US disclosed
US-8231809-B2 Solid p-semiconductors may also be used in the inventive dye-sensitized solar cells without increasing the cell resistance, since the rylene derivatives absorb strongly and therefore require only thin n-semiconductor layers BASF AKTIENGESELLSCHAFT (DE) 2012-07-31 US disclosed
US-20080269482-A1 Use of Rylene Derivatives as Photosensitizers in Solar Cells BASF SE (DE) 2008-10-30 US disclosed
EP-1951842-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS BASF SE (DE) 2008-08-06 EP disclosed
WO-2007054470-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS BASF SE (DE) 2007-05-18 WO disclosed
US-4119622-A Pyrazolonylazoaniline or aminonaphtyl compounds for copying processes BASF AKTIENGESELLSCHAFT (DE) 1978-10-10 US disclosed
US-4067903-A Manufacture of arylamines BASF AKTIENGESELLSCHAFT (DT) 1978-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283432-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS NR2E3, NR2E1, NR1D2 RAB9A 2723/4885KMT2A 908/4885ALDH1A1 4248/4885
US-20080269482-A1 Use of Rylene Derivatives as Photosensitizers in Solar Cells NR2E3, NR2E1, NR1D2 RAB9A 2723/4885KMT2A 940/4885ALDH1A1 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.